ALK rearrangement in sickle cell trait-associated renal medullary carcinoma

Genes Chromosomes and Cancer

Volumn 50, Issue 3, 2011, Pages 146-153

  Mariño Enríquez, Adrián ^a,b   Ou, Wen Bin ^a   Weldon, Christopher B ^c   Fletcher, Jonathan A ^a   Pérez Atayde, Antonio R ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HYBRID PROTEIN; ONCOPROTEIN; PROTEIN ALK; PROTEIN TYROSINE KINASE; TALIN; UNCLASSIFIED DRUG; VINCULIN;

ABDOMEN; ARTICLE; CANCER INVASION; CANCER REGRESSION; CASE REPORT; CHILD; CHROMATIN; COMPUTER ASSISTED TOMOGRAPHY; CYTOPLASM; DISEASE DURATION; ELECTRON MICROSCOPE; ELECTROPHORESIS; EOSINOPHILIA; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC ASSOCIATION; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CALCIFICATION; KIDNEY CARCINOMA; KIDNEY MEDULLA; LYMPH NODE DISSECTION; LYMPHOCYTIC INFILTRATION; MALE; MASS SPECTROMETRY; NEPHROURETERECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SICKLE CELL TRAIT; SPLEEN; THORAX; TUMOR CELL; TUMOR DIFFERENTIATION; ULTRASOUND;

CARCINOMA, RENAL CELL; CHILD; GENE REARRANGEMENT; HUMANS; KIDNEY MEDULLA; KIDNEY NEOPLASMS; MALE; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, FUSION; PROTEIN-TYROSINE KINASES; PROTEOMICS; SICKLE CELL TRAIT; VINCULIN;

EID: 78650963448     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20839     Document Type: Article

References (37)

1. Armstrong F, Duplantier MM, Trempat P, Hieblot C, Lamant L, Espinos E, Racaud-Sultan C, Allouche M, Campo E, Delsol G, Touriol C. 2004. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene 23: 6071-6082.
2. Armstrong F, Lamant L, Hieblot C, Delsol G, Touriol C. 2007. TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins. Eur J Cancer 43: 640-646.
3. Avery RA, Harris JE, Davis CJ, Jr., Borgaonkar DS, Byrd JC, Weiss RB. 1996. Renal medullary carcinoma: clinical and therapeutic aspects of a newly described tumor. Cancer 78: 128-132.
4. Bakolitsa C, Cohen DM, Bankston LA, Bobkov AA, Cadwell GW, Jennings L, Critchley DR, Craig SW, Liddington RC. 2004. Structural basis for vinculin activation at sites of cell adhesion. Nature 430: 583-586.
5. Bang Y, Kwak EL, Shaw AT, Camidge DR, Iafrate AJ, Maki RG, Solomon BJ, Ou SI, Salgia R, Clark JW. 2010. Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 28: 15S (suppl; abstr 3).
6. Berman LB. 1974. Sickle cell nephropathy. J Am Med Assoc 228: 1279.
7. Bischof D, Pulford K, Mason DY, Morris SW. 1997. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 17: 2312-2325.
8. Bohling SD, Jenson SD, Crockett DK, Schumacher JA, Elenitoba-Johnson KS, Lim MS. 2008. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma. Leuk Res 32: 383-393.
9. Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Jänne PA, Maki RG, Demetri GD, Shapiro GI. 2010. Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor. N Engl J Med 363: 1727-1733.
10. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, Nakagawara A, Hayashi Y, Mano H, Ogawa S. 2008. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455: 971-974.
11. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, Karras JG, Levy DE, Inghirami G. 2005. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11: 623-629.
12. Coogan CL, McKiel CF, Jr., Flanagan MJ, Bormes TP, Matkov TG. 1998. Renal medullary carcinoma in patients with sickle cell trait. Urology 51: 1049-1050.
13. Davis CJ, Jr, Mostofi FK, Sesterhenn IA. 1995. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Path 19: 1-11.
14. Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P, Rigal-Huguet F, al Saati T, Cerretti DP, Morris SW, Mason DY. 1997. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 89: 1483-1490.
15. Elenitoba-Johnson KS, Crockett DK, Schumacher JA, Jenson SD, Coffin CM, Rockwood AL, Lim MS. 2006. Proteomic identification of oncogenic chromosomal translocation partners encoding chimeric anaplastic lymphoma kinase fusion proteins. Proc Natl Acad Sci USA 103: 7402-7407.
16. Eng JK, McCormack AL and Yates JR. 1994. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 5: 976-989.
17. George RE, Sanda T, Hanna M, Frohling S, Luther W, II, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT. 2008. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455: 975-978.
18. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O. 2008. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455: 967-970.
19. Kuroda N, Naruse K, Miyazaki E, Hayashi Y, Yoshikawa C, Ashida S, Moriki T, Yamasaki Y, Numoto S, Yamamoto Y, Yamasaki I, Hiroi M, Shuin T, Enzan H. 2000. Vinculin: Its possible use as a marker of normal collecting ducts and renal neoplasms with collecting duct system phenotype. Mod Pathol 13: 1109-1114.
20. Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, Pinkus JL, Pinkus GS, Xiao S, Yi ES, Fletcher CD, Fletcher JA. 2000. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 157: 377-384.
21. Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, Fletcher CD, Corless CL, Fletcher JA. 2008. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 216: 64-74.
22. Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CD, Fletcher JA. 2000. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156: 791-795.
23. Marino-Enriquez A, Wang WL, Roy A, Lopez-Terrada D, Lazar AJ, Fletcher CD, Coffin CM, Hornick JL. Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol (in press).
24. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. 1994. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263: 1281-1284.
25. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM. 2008. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455: 930-935.
26. Mosse YP, Wood A, Maris JM. 2009. Inhibition of ALK signaling for cancer therapy. Clin Cancer Res 15: 5609-5614.
27. Peng J, Gygi SP. 2001. Proteomics: the move to mixtures. J Mass Spectrom 36: 1083-1091.
28. Price GJ, Jones P, Davison MD, Patel B, Bendori R, Geiger B, Critchley DR. 1989. Primary sequence and domain structure of chicken vinculin. Biochem J 259: 453-461.
29. Selby DM, Simon C, Foley JP, Thompson IM, Baddour RT. 2000. Renal medullary carcinoma: Can early diagnosis lead to long-term survival? J Urol 163: 1238.
30. Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol Epub (in press).
31. Shevchenko A, Wilm M, Vorm O and Mann M. 1996. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68: 850-858.
32. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. 2007. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566.
33. Stahlschmidt J, Cullinane C, Roberts P, Picton SV. 1999. Renal medullary carcinoma: prolonged remission with chemotherapy, immunohistochemical characterisation and evidence of bcr/abl rearrangement. Med Pediatr Oncol 33: 551-557.
34. Swartz MA, Karth J, Schneider DT, Rodriguez R, Beckwith JB, Perlman EJ. 2002. Renal medullary carcinoma: Clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urology 60: 1083-1089.
35. Wartchow EP, Trost BA, Tucker JA, Albano EA, Mierau GW. 2008. Renal medullary carcinoma: Ultrastructural studies may benefit diagnosis. Ultrastruct Pathol 32: 252-256.
36. Watanabe IC, Billis A, Guimaraes MS, Alvarenga M, de Matos AC, Cardinalli IA, Filipi RZ, de Castro MG, Suzigan S. 2007. Renal Medullary Carcinoma: report of seven cases from Brazil. Mod Pathol 20: 914-920.
37. Ziegler WH, Liddington RC, Critchley DR. 2006. The structure and regulation of vinculin. Trends Cell Biol 16: 453-460.